UroGen Pharma (URGN) investor relations material

Company overview and technology

• Developed RTGel technology enabling sustained drug delivery in the urinary tract, transforming treatment for urothelial cancers.

• First product, Jelmyto, approved in 2020 for low-grade upper tract urothelial cancer, offering a kidney-sparing alternative to surgery.

• Zosduri (UGN-102) approved by FDA in June for low-grade intermediate risk non-muscle invasive bladder cancer, targeting a much larger patient population.

Market opportunity and launch progress

• Zosduri targets 60,000 U.S. patients annually, representing a $5 billion+ market opportunity.

• Sales force expanded from 52 to 82 reps post-approval, now covering 8,500 physicians and 90% of the target market.

• Early launch shows high physician enthusiasm, strong initial demand, and broad market access with 90% of covered lives.

• Several hundred sites activated to order and administer Zosduri, with robust patient enrollment forms received.

Clinical data and patient impact

• Zosduri is the first and only FDA-approved non-surgical therapy for its indication, with 80% complete response at three months and 72% at 24 months.

• Enables office-based, ambulatory treatment, highly preferred by patients over traditional surgery.

• High patient and physician satisfaction, with 90% of surveyed patients preferring Zosduri to surgery.